Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/29402
Title: Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.
Authors: 
Keywords: 
Issue Date: Oct-2017
Citation: Breast Care (Basel).2017 Oct;(12)5:296-302
Abstract: After optimizing endocrine monotherapy modalities in the setting of advanced luminal breast cancer (BC), dual endocrine/targeted therapy combinations have been tested with positive results, and are transforming this BC subtype treatment landscape. Cell cycle deregulation is a hallmark of cancer that has become a key druggable target in hormone receptor (HR)-positive BC due to its role in endocrine resistance mechanisms. Cyclin dependent kinase (CDK)4/6 inhibitors have experienced a fast development in combination with endocrine therapy and have already been commercialized in some countries. In this review, we will summarize the development of these CDK4/6 inhibitors in luminal BC, from the preclinical data to the pivotal phase III trials that led to their approval, focusing on the efficacy and safety data for each of the treatment settings. Moreover, we will consider the challenges CDK4/6 inhibitors face in their positioning in the algorithm of treatment for advanced luminal BC and the considerations physicians should take into account when selecting these therapies for their patients. However, we are still in need of reliable predictive biomarkers in order to identify patients who will derive the greatest benefit from these drug combinations that are not exempt from toxicity.
PMID: 29234248
URI: https://hdl.handle.net/20.500.12530/29402
Rights: openAccess
ISSN: 1661-3791
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Hospitales > H. U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC5704690.pdf99.67 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.